Cerebiome® exerts a positive influence on the gut microbiota of individuals with mild anxiety, new study finds
Apsen Farmaceutica, Lallemand Health Solutions’ commercial partner in Brazil, is publishing new positive results on the influence of Cerebiome® on the gut microbiota of individuals with mild anxiety.
The positive influence of Cerebiome® on the gut microbiota of individuals with mild anxiety was demonstrated for the first time by using a dynamic microbiome model [De Oliveira et al. 2023]. The Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) model is a dynamic replica of the human gastrointestinal tract, which allowed to track probiotic passage through the stomach, small intestine, and colon of anxious donors.
“The SHIME® study reinforces our commitment to physicians and patients. By contributing to science, we are also building a more scientific base for the proper use of our products, while helping thousands of Brazilians who suffer from occasional or mild anxiety symptoms” explains Márcio Castanha, Commercial Vice-President at Apsen.
“We are very pleased of our ever-flourishing collaboration with Apsen, a partner with whom we share a similar scientific philosophy and work ethic. Our cooperation over the years has garnered the introduction of innovative probiotic solutions for the benefit of all Brazilians,” notes Edwing Koc, Sales Manager, responsible for the Latin America region at Lallemand Health Solutions.
About the study[1]
The SHIME study showed for the first time Cerebiome® ability to balance the gut microbiota and decrease the abundance of bacterial genera which are associated with anxiety symptoms and inflammation (Lachnospira and Escheria-Shigella). In addition, an increase of GABA production was observed after 14 days of probiotic intake, when compared to the control period. GABA is an important neurotransmitter in the central nervous system, for which a deficiency is usually observed in individuals with anxiety-like behaviors. Another finding reveals that the probiotic intake significantly decreased ammonia (NH4+) production, when compared to the control period. Ammonia is observed in excess in individuals with motor and cognitive dysfunctions. This new publication also confirms that Cerebiome® strains survive the gastrointestinal passage, significantly increase the SCFAs and exerts a positive effect on cytokine secretion in the gut.
These findings confirm Cerebiome® correlation on the microbiome-gut-brain axis and its promising mental health applications.
According to Dr. Katia Sivieri, researcher responsible for conducting the study, “knowledge of the microbiota signature in patients with mild anxiety disorders provides a promising direction for the mental illness prevention and opens a new perspective on the use of psychobiotics as a therapeutic intervention.”
Lallemand’s documented probiotic Cerebiome® for the gut-brain axis is offered in exclusivity by Apsen to the Brazilian market. Cerebiome® is the first probiotic formulation for the brain-gut axis on the Brazilian market, with approved health claims by the Brazilian Health Authorities (ANVISA).
Cerebiome® (a proprietary combination of L. helveticus Rosell®-52 and B. longum Rosell®-175) is the most documented psychobiotic in the world, with six clinical studies and several pre-clinical studies allowing to highlight eight mechanisms of action on the gut-brain axis. Its array of evidence has led to significant results showing Cerebiome® promotes positive mood in times of stressful events and helps moderate physiological (Diop 2008) and psychological (Messaoudi 2010, 2011) responses to occasional stress. CEREBIOME® is the first and only probiotic with authority-approved health claims on the gut-brain axis.
Headquartered in Santo Amaro, São Paulo – SP, Apsen is a Brazilian pharmaceutical company that invests in research and innovation to market 54 products, 14 of which are exclusive. Founded more than 52 years ago by a couple of Italian immigrants, today the company employs 1,800 people. Focused on branded products, Apsen is present in the main therapeutic areas: neurology, psychiatry, otorhinolaryngology, urology, gynecology, rheumatology, orthopedics, gastroenterology, geriatrics, endocrinology, angiology, nephrology, dermatology and is growing every day in over-the-counter medicines and functional foods. More information here.
About Lallemand Health Solutions
As one of Lallemand business units, Lallemand Health Solutions is a pioneering company recognized as a vertically integrated lab to shelf global leader in the manufacturing of probiotic yeast and bacteria-based formulas for human health supplements, for food applications, and nutricosmetics. Lallemand Health Solutions documented probiotics deliver gut, immune, mental, women, skin, oral, and metabolic health benefits. With its manufacturing processes adhering to the highest quality standards, including Good Manufacturing Practices, and its ambitious research program, Lallemand Health Solutions provides distributors probiotic strains that enhance life in countless ways. Over 600 probiotic formulas are currently marketed in over 60 countries across five continents.
Media contact
Lallemand Health Solutions
Marilou Luneau, Content Manager
mluneau@lallemand.com
Apsen Farmaceutica
Camilie Cardoso, Content Manager
Camilie.Cardoso@apsen.com.br
